Media Articles Related to Coartem (Artemether / Lumefantrine)
Vector immunoprophylaxis protects mice against malaria
Source: Immune System / Vaccines News From Medical News Today [2014.08.14]
A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria.
Malaria medicine chloroquine inhibits tumor growth and metastases
Source: Cancer / Oncology News From Medical News Today [2014.08.13]
The anti-cancer effect of the antimalarial agent chloroquine when combined with conventional chemotherapy has been well documented in experimental animal models.
Monthly treatment reduces malaria risk in young children
Source: Tropical Diseases News From Medical News Today [2014.08.07]
A year-round preventive drug treatment substantially reduces young children's risk of contracting malaria and poses no serious risk of adverse events, according to a study by researchers funded by...
Common anti-malarial drug effective in controlling asthma
Source: Respiratory / Asthma News From Medical News Today [2014.08.05]
NUS team discovers that artesunate, a common herbal-based anti-malarial drug, can be used to control asthma, with better treatment outcomes than other drugs currently available.
Pregnant women are often given inappropriate treatment for malaria
Source: Pregnancy / Obstetrics News From Medical News Today [2014.08.05]
Not all pregnant women with symptoms of malaria seek care from their formal healthcare system and if they do seek care, they may be given inappropriate treatment because healthcare providers often...
Published Studies Related to Coartem (Artemether / Lumefantrine)
Intermittent preventive therapy for malaria with monthly artemether-lumefantrine
for the post-discharge management of severe anaemia in children aged 4-59 months
in southern Malawi: a multicentre, randomised, placebo-controlled trial. 
reduced this risk... INTERPRETATION: In areas with intense malaria transmission, chemoprevention with
The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial. [2011.05]
CONCLUSIONS: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale. TRIAL REGISTRATION: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07.
Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. [2011.05]
The therapeutic efficacy and effects of artemether-lumefantrine (AL) and artesunate-amodiaquine co-formulated (AAcf) or co-packaged (AAcp) on malaria-associated anemia (MAA) were evaluated in 285 children < 12 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive one of the three drug combinations...
Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. [2011.04.01]
BACKGROUND: We assessed the efficacy, effectiveness and safety of artemether-lumefantrine, which is the most widely used artemisinin-based combination therapy in Africa, against Plasmodium falciparum malaria during an extended follow-up period after initial and repeated treatment... CONCLUSIONS: Artemether-lumefantrine was highly efficacious even after unsupervised administration, despite significantly lower lumefantrine concentrations, compared with concentration achieved with supervised intake, and was well-tolerated and safe after initial and repeated treatment. CLINICAL TRIAL REGISTRATION: ISRCTN69189899. (c) The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote d'Ivoire. [2011.03]
OBJECTIVES: To test the hypothesis that Artesunate-mefloquine paediatric (AS+MEF) is as effective as Artemether-lumefantrine (AL) in treating acute uncomplicated malaria in children... CONCLUSION: AS+MEF is as effective as AL, and both combinations were efficacious and safe. (c) 2011 Blackwell Publishing Ltd.
Clinical Trials Related to Coartem (Artemether / Lumefantrine)
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria [Recruiting]
The purpose of this study is to describe the pediatric and adult patients (U. S. and foreign
residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to
their demographics, including evaluation of their malaria immune status, treatment
effectiveness, prior and concomitant medication use, and the occurrence of adverse events in
association with artemether-lumefantrine treatment, based on the information collected in
the CDC Malaria Case Surveillance Report Form.
Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients [Recruiting]
There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving
antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients
are at an increased risk of contracting malaria. Increasing resistance to anti-malarials
such as chloroquine, amodiaquine, fansidar, sulphadoxine-pyrimethamine in East and West
Africa has led the WHO to recommend artemether-lumefantrine (Coartem®- Novartis) as first
line therapy for malaria for adults and children. As early as 2004, fourteen countries in
sub-Saharan Africa had adopted this guideline as national policy.
There are no data on the interaction between Coartem® and any of the antiretroviral agents.
Both components of CoartemĀ® are substrates for the 3A4 isoform of cytochrome P450. Despite
the lack of data, antiretroviral drugs and/or antituberculous drugs in addition to CoartemĀ®
are of necessity co-prescribed daily in the African setting. Nevirapine, efavirenz and
rifampicin are known inducers of cytochrome P450 3A4. A technical consultation convened by
WHO in June, 2004 concluded that additional research on interactions between antiretroviral
and antimalarial drugs is urgently needed.
We propose to perform a suite of pharmacokinetic studies to evaluate these interactions in
HIV infected Ugandan patients. The aim of these studies is to evaluate the pharmacokinetic
interaction between CoartemĀ® and commonly co-prescribed inducers of 3A4 i. e. nevirapine,
efavirenz and rifampicin.
1. Comparison of steady state pharmacokinetics of CoartemĀ® in HIV-infected patients prior
to commencement of nevirapine and at nevirapine steady state
2. Comparison of steady state pharmacokinetics of CoartemĀ® in HIV-infected patients prior
to commencement of efavirenz and at efavirenz steady state
3. Comparison of steady state pharmacokinetics of CoartemĀ® in Ugandan patients at
rifampicin steady state and without rifampicin
Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission [Recruiting]
The purpose of this study is to determine the safety and impact of ivermectin, administered
as single or repeated dose, in combination with artemether-lumefantrine in reducing the
proportion of mosquitoes that survive and become infected after feeding on a blood meal from
a malaria-infected individual.
Studies of a Candidate Aminoquinoline Antimalarial (AQ-13) [Not yet recruiting]
This is an initial efficacy study of a candidate antimalarial in human subjects with
uncomplicated malaria caused by the most common and most important parasite in Africa
(Plasmodium falciparum). This study will enroll 66 adult Malian males with uncomplicated P.
falciparum malaria and randomize them to treatment with 1750 mg of the investigational drug
(AQ-13) by mouth over 3 days or the current standard treatment, which is 4 tablets of
Coartem twice daily for 3 days. The hypothesis underlying this study is that AQ-13 will be
similarly effective to Coartem for the treatment of uncomplicated P. falciparum malaria due
to both chloroquine-susceptible and chloroquine-resistant parasites.
Reports of Suspected Coartem (Artemether / Lumefantrine) Side Effects
Wrong Drug Administered (5),
Acute Respiratory Distress Syndrome (5),
Drug Ineffective (2),
Condition Aggravated (2),
Blood Bilirubin Increased (1),
Abortion Spontaneous (1),
Protein Total Increased (1), more >>